NCT02771574View on ClinicalTrials.gov

Efficacy, Tolerability and Pharmacokinetics of Subcutaneous Exendin (9-39) in Patients With Post Bariatric Hypoglycemia

PHASE2CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

May 31, 2016

Primary Completion Date

June 30, 2017

Study Completion Date

June 30, 2017

Conditions
Post Bariatric Hypoglycemia
Interventions
DRUG

Lyo avexitide

Lyophilized avexitide (Lyo avexitide) administered subcutaneously (sc)

DRUG

Liq avexitide

Liquid avexitide (Liq avexitide) administered subcutaneously (sc)

Trial Locations (1)

94305

Stanford University School of Medicine, Stanford

Sponsors

Collaborators (1)

Eiger BioPharmaceuticals
All Listed Sponsors
collaborator

Eiger BioPharmaceuticals

INDUSTRY

lead

Tracey McLaughlin

OTHER

NCT02771574 - Efficacy, Tolerability and Pharmacokinetics of Subcutaneous Exendin (9-39) in Patients With Post Bariatric Hypoglycemia | Biotech Hunter | Biotech Hunter